Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced that data from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) will be presented in two poster sessions at the European Respiratory Society (ERS) Congress 2025 in Amsterdam. The presentations will focus on the efficacy, safety, and responder analysis of nalbuphine ER in treating refractory chronic cough (RCC).

The posters will be presented on September 28-29, 2025, covering results from the trial investigating Haduvio™ for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and RCC.

NEW HAVEN, Conn., Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that data from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC, will be highlighted in two poster presentations at the European Respiratory Society (ERS) Congress 2025. ERS will be held from September 27 to October 1 in Amsterdam, Netherlands.

Abstract: Late Breaking Abstract - Efficacy and safety of nalbuphine extended-release in refractory chronic cough: results from the phase 2a RIVER trial
Poster Session: 305 – Rethinking Cough: From Mechanism to Management
Session Date & Time: September 29, 12:30-2:00pm CEST
Location: PS-14

Abstract: Late Breaking Abstract - Responder analysis of nalbuphine extended-release in refractory chronic cough: results from the RIVER phase 2a trial
Poster Session: 158 – Lung Physiology in Interstitial Lung Disease
Session Date & Time: September 28, 12:30-2:00pm CEST
Location: PS-6

Registration Details

About the Phase 2a RIVER Trial
The Phase 2a Refractory Chronic Cough Improvement Via Nalbuphine ER (RIVER) trial was a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, and tolerability of nalbuphine ER for the treatment of patients with RCC. Each treatment period lasted 21 days, separated by a 21-day washout period. During the nalbuphine ER treatment period, patients were titrated with assessments at 27 mg twice daily (BID), 54 mg BID, and 108 mg BID for objective cough and other assessments at each dose. The primary endpoint of the trial was the mean change in 24-hour cough frequency, as determined by an objective cough monitor, for the full analysis set (FAS) population at Day 21. The FAS population included all patients who received at least one dose of study drug and have objective cough count data on both Baseline and Day 21 in at least one treatment period.

About Refractory Chronic Cough (RCC)
Refractory chronic cough is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. 

Investor Contact 
Jonathan Carlson 
Trevi Therapeutics, Inc. 
(203) 654 3286 
carlsonj@trevitherapeutics.com 

Media Contact 
Rosalia Scampoli 
914-815-1465 
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-two-posters-from-the-phase-2a-river-trial-data-will-be-featured-at-the-european-respiratory-society-ers-congress-2025-302559765.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When will Trevi Therapeutics (TRVI) present its RIVER trial data at ERS Congress 2025?

Trevi will present two posters on September 28 and 29, 2025, between 12:30-2:00pm CEST at the ERS Congress in Amsterdam.

What is the purpose of Trevi Therapeutics' Haduvio treatment?

Haduvio (nalbuphine ER) is being developed for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough (RCC).

What type of data will TRVI present at the ERS Congress 2025?

TRVI will present data on the efficacy, safety, and responder analysis of nalbuphine ER from their Phase 2a RIVER trial in refractory chronic cough patients.

Where will the ERS Congress 2025 featuring TRVI's presentations be held?

The ERS Congress 2025 will be held in Amsterdam, Netherlands from September 27 to October 1.